Definitive Contract 75N93023C00002
Award Date 11/1/22
Potential Completion Date 5/31/27
Potential Value $14M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Portland, OR 97239, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded a $38.21 million definitive contract to The Leland Stanford Junior University for development of small synthetic chemical molecules as broadly active antivirals for treatment of viral infections on September 1, 2020. The contract carries cost-plus-no-fee pricing and runs through May 31, 2030. Work is performed in Palo Alto, California. The originating solicitation, posted as a pre-solicitation notice in December 2019, sought...
- The National Institute of Allergy and Infectious Diseases awarded a $14.2 million definitive contract to Microbiotix, Inc. for development of the PPZ series of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies, effective November 1, 2022. The contract is structured as cost-plus-fixed-fee with an ultimate completion date of March 1, 2028. Place of performance is Worcester, MA. The originating Broad...
- This is a $10,725,896 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Oregon Health & Science University (OHSU). The contract is for the Vaccine Adjuvant Discovery Program, which aims to identify novel adjuvant candidates that can enhance the efficacy of human vaccines. The contract is a definitive, cost-no-fee contract with a performance period ending on March 31, 2026. No set-aside was...
- The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Access To Advanced Health Institute for multivalent flavivirus vaccine development using a flexible replication RNA platform on September 9, 2019, with a ceiling value of $16.7 million under a cost-plus-fixed-fee structure. Place of performance is Seattle, WA. The originating opportunity (HHS-NIH-NIAID-BAA2018) calls for development of a multivalent flavivirus vaccine leveraging systems immunology...
- The National Institute of Allergy and Infectious Diseases awarded an $8.7 million firm fixed-price definitive contract to the University of California San Diego, Scripps Institution of Oceanography for development of a small-molecule dual adjuvant system for influenza virus vaccine on September 30, 2023, with ultimate completion on September 29, 2028. Place of performance is La Jolla, CA. The contract operates on a full-and-open basis with no set-aside. In FY2024, the contract invoiced $2.4...
- The National Institute of Allergy and Infectious Diseases awarded a $23.878 million definitive contract to Arisan Therapeutics Inc. on August 3, 2026, to develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection. The contract is priced on a cost-plus-fixed-fee basis with no set-aside category. Place of performance is Carlsbad, CA. The originating opportunity was posted as a pre-solicitation Broad Agency Announcement on November 4, 2024, with...
- The National Institute of Allergy and Infectious Diseases awarded a $32.3 million cost-plus-fixed-fee definitive contract to Baruch S. Blumberg Institute on November 15, 2022, to develop an orally available small molecule antiviral drug for treatment of yellow fever virus infection as the primary indication. Place of performance is Doylestown, PA. The contract carries ultimate completion by November 30, 2027. The originating solicitation was a Broad Agency Announcement from NIAID issued...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on July 27, 2021, with a ceiling value of $630,604.13 for GMP manufacturing of oxfendazole clinical trial material and stability study work under the Nonclinical Services for Development of Interventional Agents master IDIQ. Place of performance is Menlo Park, CA. The order's ultimate completion date is June 2, 2025. Pricing is cost-plus-fixed-fee with no set-aside applied. Service Contract...
- The National Institute of Allergy and Infectious Diseases awarded a $6.44 million definitive contract to The University of Chicago for bioinformatics resource centers for infectious diseases on September 15, 2019, on a cost-no-fee basis with a ceiling value of $42.69 million. The contract's ultimate completion date is September 14, 2024. Place of performance is Chicago, IL. The award was structured in part to administrate de-obligation of unexpended and expiring fiscal year 2021 funding in...
- The National Institute of Allergy and Infectious Diseases awarded a $9.3 million cost-no-fee definitive contract to University Of Tennessee Health Science Center on August 3, 2026, to conduct investigational new drug-enabling studies of a pre-clinical candidate for treatment of neurotropic alphaviruses. Performance occurs in Memphis, Tennessee, with work completed by July 31, 2028. The originating solicitation was a Broad Agency Announcement (BAA) posted November 4, 2024, focused on advancing...